|
 |
|
 |
|
Acomplia Clinical Trials |
Acomplia is a product of 2 years of clinical which have proven its efficacy for weight loss. Clinical trial is wished-for to validate the efficacy of an amalgam for human use. It can be administered only subsequent to satisfactory confirmation in preclinical studies. Clinical trial is crucial in determining the effectual dosage plan, probable toxicity and the character and frequency of undesirable events it may cause.
Clinical trials of Acomplia (Rimonabant) were conducted along 3 successive phases. In Phase I was made to evaluate its safety, its bodily evolvement, the acceptance limit and detrimental events. Phase II was undertaken to check its effectiveness and conclude most favorable dosage routine. Lastly, the Phase III was undertaken to analyze the role of its active ingredient Rimonabant in obesity managed - weight maintenance or weight loss; prevention of weight regain subsequent to previous weight loss; and improvement of menace factors associated to obesity.
It is to be noted that trials do not come to an abrupt end once the product has been made available in the market; they continue all throughout its selling life.
The function of Rimonabant in termination of smoking and long-term self-restraint and prevention of weight gain even after smoking cessation was also tested. Conclusion of the first trial reflected comparative potential; however consequences of the other two trials were never disclosed. The U.S. FDA (Food and Drug Administration) and even EMEA (European medicines Agency) has not until now provided it approval as a smoking cessation support.
|
|
|
 |
|
 |
|
|
|
|
